A remodeled CAR T-cell therapy causes fewer neurologic side effects and is equally effective as the original form of the treatment, according to results from the first clinical trial testing the approach in patients with B-cell lymphomas.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/38JMb11
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/38JMb11